WELL Health Technologies Corp (WELL) AI Stock Analysis

• Market Cap: C$1.01B
• Dividend Yield: N/A
• Average Volume (3M): 1.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: 26.20%
• EPS Growth: -156.86%
• Country: CA
• Employees: 1,507
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.16
• Shares Outstanding: 253,882,260
• 10 Day Avg. Volume: 1,712,971
• 30 Day Avg. Volume: 1,366,290
• PEG Ratio: <0.01
• Price to Book (P/B): 1.95
• Price to Sales (P/S): 1.84
• P/FCF Ratio: -252.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$7.60
• Price Target Upside: 90.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: C$4.00 ▲(0.25% Upside)

WELL Health Technologies Corp's overall score is driven by strong earnings call results and positive corporate events, indicating growth potential. However, financial performance and valuation concerns, along with bearish technical indicators, moderate the overall score.

Positive Factors

Revenue Growth

The significant year-over-year revenue growth indicates strong market demand and effective business strategies, enhancing long-term market position.

EBITDA Improvement

The substantial increase in EBITDA reflects improved operational efficiency and cost management, supporting sustainable profitability.

Canadian Clinics Performance

The robust growth in Canadian clinics underscores the company's strong market presence and potential for continued expansion in healthcare services.

Negative Factors

Profitability Challenges

Ongoing profitability issues could hinder reinvestment and growth opportunities, affecting long-term financial health and shareholder returns.

Cash Flow Management

Negative free cash flow indicates potential liquidity issues, limiting the company's ability to fund operations and strategic initiatives.

Circle Medical Performance

Declining revenues in Circle Medical highlight operational challenges that could impact overall growth and require strategic adjustments.

WELL Health Technologies Corp Business Overview & Revenue Model

Company Description

WELL Health Technologies Corp (WELL) is a Vancouver-based digital health company focused on empowering healthcare providers and patients through innovative technology solutions. The company operates primarily in the healthcare sector, offering a range of services that include telehealth, electronic medical records (EMR) solutions, and patient engagement platforms. WELL's core products aim to enhance access to healthcare, streamline clinical workflows, and improve patient outcomes, making it a key player in the digital transformation of healthcare services.

How the Company Makes Money

WELL Health generates revenue through multiple streams, primarily by providing software and technology solutions to healthcare providers. Key revenue sources include subscription fees for its EMR systems, transaction fees from telehealth consultations, and sales of patient engagement tools. Additionally, WELL benefits from partnerships with various healthcare organizations and institutions, which enable it to expand its service offerings and reach a broader customer base. The company also explores opportunities in acquisitions to enhance its technology portfolio and increase market share, contributing to its overall earnings.

WELL Health Technologies Corp Financial Statement Overview

Summary

WELL Health Technologies Corp shows strong revenue growth but faces challenges in profitability and cash flow management. The balance sheet is stable, but negative profitability and cash flow conversion issues need addressing.

Income Statement

WELL Health Technologies Corp has shown a positive revenue growth rate of 11.56% in the TTM, indicating a strong upward trajectory in sales. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased over time, reflecting potential cost management issues.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.57, suggesting a balanced approach to leveraging. However, the negative return on equity in the TTM indicates challenges in generating returns for shareholders. The equity ratio is stable, showing a solid capital structure.

Cash Flow

The cash flow statement reveals a significant improvement in free cash flow growth rate, but the free cash flow remains negative. The operating cash flow to net income ratio is low, indicating potential issues in converting income into cash. The free cash flow to net income ratio is also negative, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.21B	919.69M	776.05M	569.14M	302.32M	50.24M
Gross Profit	456.62M	363.01M	372.27M	303.29M	153.69M	21.22M
EBITDA	80.72M	122.52M	101.88M	95.07M	21.27M	-495.00K
Net Income	-43.25M	32.61M	82.00K	19.07M	-30.69M	-2.62M
Balance Sheet
Total Assets	2.02B	1.81B	1.41B	1.32B	1.26B	262.73M
Cash, Cash Equivalents and Short-Term Investments	82.55M	131.67M	43.42M	48.91M	61.92M	86.89M
Total Debt	624.13M	425.09M	426.28M	358.42M	401.94M	23.57M
Total Liabilities	1.03B	877.55M	563.16M	503.78M	554.37M	43.75M
Stockholders Equity	844.39M	867.61M	767.67M	732.34M	618.24M	217.37M
Cash Flow
Free Cash Flow	-52.10M	-6.70M	37.20M	70.14M	19.59M	-6.52M
Operating Cash Flow	-26.75M	9.52M	66.44M	76.55M	22.27M	-5.38M
Investing Cash Flow	-106.48M	-60.23M	-106.42M	-37.93M	-499.78M	-44.21M
Financing Cash Flow	147.61M	133.50M	10.63M	-52.85M	452.53M	120.84M

WELL Health Technologies Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:WELL, the sentiment is Negative. The current price of 3.99 is above the 20-day moving average (MA) of 3.91, below the 50-day MA of 4.46, and below the 200-day MA of 4.51, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 41.10 is Neutral, neither overbought nor oversold. The STOCH value of 29.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:WELL.

WELL Health Technologies Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DR	72 Outperform	C$278.92M	2.16	39.85%	2.33%	-40.05%	558.77%
NLH	70 Outperform	C$27.94M	26.67	4.10%	―	19.61%	―
DNTL	68 Neutral	C$2.18B	-78.05	-1.56%	0.69%	10.09%	67.54%
WELL	59 Neutral	C$1.01B	-22.45	-5.11%	―	26.20%	-156.86%
CRRX	59 Neutral	C$242.91M	3,870.00	0.11%	0.52%	0.19%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

WELL Health Technologies Corp Corporate Events

WELL Health Technologies Reports Robust Growth and Advances in Clinic Digitization

WELL Health Technologies Corp reported strong organic growth with a 41% year-over-year increase in quarterly revenue, driven by significant advances in clinic digitization and the opening of new primary care patient slots. The company has achieved 92% digitization in its primary care clinics and has already filled 25,000 of the 45,000 new patient openings, reflecting its commitment to expanding access to care and enhancing operational efficiency.

WELL Health Technologies Achieves Strong Growth and Advances in Clinic Digitization

WELL Health Technologies Corp reported significant growth in its Canadian Patient Services business, achieving over $110 million in quarterly revenue, a 41% increase year-over-year. The company has made substantial progress in digitizing its clinics, reaching 92% digitization for primary care clinics in its network for over nine months. Additionally, WELL has successfully opened 25,000 new primary care patient slots out of the 45,000 planned, with expectations to fill the remainder by the end of Q1. These advancements underscore WELL’s commitment to enhancing operational efficiency and expanding healthcare access through technology.

WELL Health Technologies Corp Announces Major Growth Milestones

WELL Health Technologies Corp’s subsidiary, WELLSTAR, has announced significant developments, including a major eReferral contract for its OceanMD platform, boosting its annual recurring revenue by 16%. The company has also completed strategic acquisitions and a $62 million financing round, positioning itself as a leader in Canada’s digital health market. These moves are part of WELLSTAR’s strategy to expand its market reach and enhance its offerings, with a potential public listing in 2026.

WELL Health Technologies’ WELLSTAR Achieves Significant Growth and Secures Major Contract

WELL Health Technologies Corp’s subsidiary, WELLSTAR, has achieved significant growth through both organic and inorganic means. OceanMD, a leader in Canada’s eReferral market, has secured a major contract with a Canadian province, boosting WELLSTAR’s annual recurring revenue by 16%. Additionally, WELLSTAR has completed several strategic acquisitions and raised $62 million to support its growth initiatives, positioning itself as a premier digital health platform in Canada.

WELL Health Technologies Achieves Record Q3-2025 Financial Results

WELL Health Technologies Corp reported record financial results for Q3-2025, with revenues reaching $364.6 million, a 56% increase from the previous year, driven by organic growth and acquisitions. The company achieved a record Adjusted EBITDA of $59.9 million, marking a 296% increase, and highlighted improvements in operational efficiency and patient visits in its Canadian clinics. WELLSTAR, a majority-owned subsidiary, secured $62 million in financing, reflecting strong market confidence and positioning it for future growth and an IPO.

WELLSTAR Technologies Secures C$62 Million for Growth Ahead of Spinout

WELL Health Technologies Corp’s subsidiary, WELLSTAR Technologies, has announced a C$62 million equity placement to support its growth strategy ahead of a planned spinout. The financing, backed by prominent Canadian investors, is expected to close in December 2025 and will be used for AI innovation, acquisitions, and organic growth. This move highlights investor confidence in WELLSTAR’s performance and positions the company for a public listing in 2026, offering direct investment opportunities in a high-growth healthcare technology firm.

WELL Health Technologies to Release Q3 2025 Financial Results

WELL Health Technologies Corp. announced it will release its Fiscal Third Quarter 2025 financial results on November 6, 2025. The company will hold a conference call and webcast on the same day to discuss the results, which could provide insights into its operational performance and market positioning.